BiondVax Pharmaceuticals Ltd. (BVXV): Price and Financial Metrics


BiondVax Pharmaceuticals Ltd. (BVXV): $2.43

0.11 (+4.74%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

BVXV Stock Price Chart Interactive Chart >

Price chart for BVXV

BVXV Price/Volume Stats

Current price $2.43 52-week high $43.57
Prev. close $2.32 52-week low $2.10
Day low $2.26 Volume 96,200
Day high $2.44 Avg. volume 694,152
50-day MA $2.60 Dividend yield N/A
200-day MA $3.38 Market Cap 27.59M

BiondVax Pharmaceuticals Ltd. (BVXV) Company Bio


Biondvax Pharmaceuticals Limited is a pharmaceutical company that develops intra-nasal flu vaccines.


BVXV Latest News Stream


Event/Time News Detail
Loading, please wait...

BVXV Latest Social Stream


Loading social stream, please wait...

View Full BVXV Social Stream

Latest BVXV News From Around the Web

Below are the latest news stories about BiondVax Pharmaceuticals Ltd that investors may wish to consider to help them evaluate BVXV as an investment opportunity.

Cathie Wood Is Selling These 10 Stocks

In this article, we discuss the 10 stocks Cathie Wood is selling. If you want to skip our detailed analysis of these stocks, go directly to Cathie Wood Is Selling These 5 Stocks. There are few institutional investors who are willing to take risks on high growth stocks because of the price volatility and the […]

Yahoo | September 15, 2021

BiondVax Announces Second Quarter 2021 Financial Results and Provides Business Update

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today published its second quarter financial results for the quarter ended June 30, 2021.

Yahoo | August 26, 2021

The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck

Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV ) Alkermes plc (NASDAQ: ALKS ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX ) Gilead Sciences, Inc. (NASDAQ: GILD ) GlaxoSmithKline plc (NYSE: GSK ) ( announced FDA approval for label expansion for its Jemperli) Novo Nordisk A/S (NYSE: NVO ) Innoviva, Inc. (NASDAQ: INVA ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI ) Omega Therapeutics, Inc. (NASDAQ: OMGA ) (IPOed July 30) Pfizer, Inc. (NYSE: PFE ) Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) ResMed Inc. (NYSE: RMD ) TScan Therapeutics, Inc. (NASDAQ: TCRX ) Virpax Pharmaceutical...

Benzinga | August 19, 2021

BiondVax Announces First Quarter 2021 Financial Results and Provides Business Update

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today published its first quarter financial results for the quarter ended March 31, 2021. A summary is included in the tables below.

Yahoo | June 23, 2021

BiondVax Pharmaceuticals Ltd. (BVXV): Hedge Funds Are Snapping Up

No summary available.

Insider Monkey | June 15, 2021

Read More 'BVXV' Stories Here

BVXV Price Returns

1-mo 13.02%
3-mo -19.54%
6-mo -39.55%
1-year -94.28%
3-year -57.52%
5-year N/A
YTD -13.52%
2020 -69.75%
2019 94.76%
2018 -11.01%
2017 60.00%
2016 -15.40%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9882 seconds.